Clinical Trial

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

Study acronym: Ava dosing
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2025 (before its estimated July 8, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and continued for up to 24 weeks. The study aims to acquire experience on use of avatrombopag and explore the efficacy and safety of lower starting dose of avatrombopag
Trial Details
NCT Number NCT07133659
Lead Sponsor Al-Mustansiriyah University
Conditions ITP - Immune Thrombocytopenia
Enrollment 25 participants
Start Date 2025-06-08
Primary Completion 2026-07-08 (estimated)
Study Completion 2027-07-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-21